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performed only on these patients. There were 2,014 wound episodes among the 861 patients, but only 976 wound episodes had adequate treatment information for inclusion in the analysis. Of the 861 eligible patients, 473 were not prescribed a wound-healing product, 49 (5.7%) received BCT, 77 (8.9%) received BCT+O and 262 (30.4%) received Other. Of the 2,014 wound episodes included in the analysis, 649 had available MDS outcome data, 49 of which were treated with BCT, 124 with BCT+O and 476 with Other alone.
Study design
The study was a retrospective cohort study.
Analysis of effectiveness
It was difficult to determine the unit of analysis and number of patients or wound episodes included in each of the study analyses, as it seemed to vary between analyses. The authors conducted complete case analyses. It was also unclear as to whether analyses based on wound episodes were adjusted for clustering by patient. The primary health outcomes were healing rate, time to heal and duration of treatment. The authors did not describe how comparable the groups were at baseline, but they stated that any covariates that were statistically significant at baseline were included in adjusted analyses for certain key outcome measures.
Effectiveness results
The adjusted healing rate was significantly higher for patients receiving BCT (58.6%) than for those receiving Other (37.1%) or BCT+O (42.8%), (p<0.05), based on an analysis of covariance (ANCOVA). These findings were not statistically significant if Stage 1 and Stage 2 ulcers were analysed separately.
The adjusted mean time to heal was 31.3 days (95% CI: -7.7 to 70.4) for BCT, 74.9 days (95% CI: 42.6 to 107.2) for BCT+O and 62.3 days (95% CI: 45.5 to 79.2) for Other. The differences were not found to be statistically significant.
The mean duration of treatment was significantly shorter for patients receiving BCT than for those receiving BCT+O or Other, (p<0.001).
Clinical conclusions
The authors concluded that BCT and BCT+O produce better healing outcomes than Other treatments.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis. In effect, the study was a cost-consequences analysis.
Direct costs
The resource use quantities were not reported separately from the costs. The study included the direct costs to SNFs. Nursing labour cost was the only cost included in the analysis. Labour time and wages were estimated from MDS records. The study reported the mean daily costs. The price year was not reported.
Statistical analysis of costs
The authors reported the mean costs with 95% CIs. The costs were compared using ANCOVA. ANCOVA relies on the assumption that the dependent variable, in this case costs, is normally distributed. This might have been appropriate for an analysis of the mean daily cost but the authors did not comment on the underlying distribution. The authors stated that they also employed post-hoc statistical techniques such as the Tukey method of multiple comparisons. The study is unlikely to have been sufficiently powered to detect a difference in the costs.
Indirect Costs
The indirect costs were not included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
Not relevant.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
For patients whose initial wound was Stage 1, the mean daily labour costs were $50.8 (95% CI: 47.1 to 54.4) for BCT, $54.5 (95% CI: 48.9 to 60.1) for BCT+O and $61.7 (95% CI: 58.7 to 64.7) for Other.
For patients whose initial wound was Stage 2, the mean daily labour costs were $58.1 (95% CI: 53.5 to 62.8) for BCT, $63.4 (95% CI: 60.0 to 66.8) for BCT+O and $62.3 (95% CI: 60.7 to 63.9) for Other.
The mean daily labour cost for patients treated with BCT was significantly lower than for those treated with BCT+O or Other for patients whose initial or highest ulcer stage was Stage 1, (p<0.05).
Synthesis of costs and benefits
